The first-line treatment for unresectable hepatocellular carcinoma patients: lenvatinib versus sorafenib, or beyond?
Hepatobiliary Surg Nutr
.
2018 Jun;7(3):221-224.
doi: 10.21037/hbsn.2018.06.06.
Authors
Feihu Xie
#
1
,
Shi Feng
#
1
,
Lejia Sun
1
,
Yilei Mao
1
Affiliation
1
Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
#
Contributed equally.
PMID:
30046580
PMCID:
PMC6036058
DOI:
10.21037/hbsn.2018.06.06
No abstract available
Publication types
Comment